Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest James Freeman Stories

2010-11-05 10:51:10

(Ivanhoe Newswire) -- The recent approval of a drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm. It may also offer patient's better health outcomes than the commonly prescribed and potentially risky blood thinner, warfain. "Dabigatran is the first new drug in 20 years to be approved for stroke prevention in atrial fibrillation, and we wanted to see if it could be cost-effective even before it made its debut in the United States," cardiac...

2010-11-02 15:20:21

A newly approved drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm "” and may also offer patients better health outcomes than the commonly prescribed, but potentially risky, blood thinner warfarin. That's according to a new analysis from researchers at the Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System. "Dabigatran is the first new drug in 20 years to be approved for stroke prevention in atrial...